"Reliable Peptide
Yields In Your
Timeline"
Neoantigens may require different yields, TAT, number, purity, ect, depending on their downstream
application. To accommodate the needs of the neoantigen community, ALL of
GenScript’s
neoantigen peptide services are fully flexible and customizable.
Example Project 1: TCR Affinity and Immunogenicity
Screening
GenScript offers a wide range of services to fit the needs of customers working on the beginning
stages of
T-cell therapy to clinical stage efficacy screening. Learn the various ways GenScript’s neoantigen
peptide
synthesis service can be customized to fit the peptide requirements of each phase, even including
TCR
affinity maturation and epitope identification! Read More »
Project Goal: Generate an Allogenic T-cell Therapy for Patient with Squamous
Cell
Carcinoma
Phase I: Phase I: After tumor biopsy and NGS, 300 different neoantigens were
identified
as possible candidates. These sequences were sent to GenScript to synthesize as a crude peptide
library
to be used for in-vitro functionality screening of TCR Binding Affinity and
Efficacy.
Phase II: In-vitro functionality screening identified a top candidate, however,
in order
to increase the binding affinity and efficacy of the TCR, researchers decided to design and
generate an
overlapping library to map the specific interaction between neoantigen epitope and TCR.
Phase III: Once the specific epitope was identified, researchers designed and
generated
an alanine scanning library to determine which amino acids were most important for therapeutic
efficacy,
prior to affinity maturation of the TCR.
Example Project 2: PCV Development
When generating a PCV, researchers require an array of peptide services due the specific needs of in
vitro
functionality screening, pre-clinical safety basement in laboratory models, and clinical efficacy
analysis.
Learn how GenScript’s neoantigen peptide synthesis service has flexible services which allow for
reliable
peptides for any phase of PCV development. Read More »
Project Goal: Generate a Personalized Cancer Vaccine for a patient with
Glioblastoma
Phase I: After tumor biopsy and NGS, 150 different neoantigens were identified
as
possible candidates. These sequences were sent to GenScript to synthesize as a purified peptide
library
to be used for in-vitro functionality screening.
Phase II: In-vitro functionality screening identified 20 peptides for
pre-clinical PCV development for non-human primate.
Phase III: After the vaccine was deemed “safe” through pre-clinical testing; the
vaccine
was used in a human patient. After inoculation, researchers required “vaccine” and “non-vaccine
control”
neoantigen peptides for clinical in-vitro efficacy screening of patient derived
PBMC’s.
